Nkarta, Inc. Insider Transaction Details

Nkarta, Inc. (NASDAQ:NKTX) recently witnessed an insider sale as David Shook, a company insider, sold 8,638 shares on January 15th. The shares were transacted at an average price of $2.20, resulting in a total sale value of $19,003.60. Post-transaction, Shook retains ownership of 190,955 shares, amounting to a current value of $420,101. This transaction reflects a 4.33% reduction in their ownership stake in the company. The details of this sale are recorded in a filing with the Securities and Exchange Commission (SEC), which can be reviewed on the SEC's official website.

Nkarta Stock Performance

On a recent trading day, Nkarta's stock price declined by 0.8%, closing down $0.02 to reach $2.47. The trading volume for the day was reported at 1,770,362 shares, exceeding the average volume of 1,352,778. Currently, Nkarta has a 50-day moving average of $2.54 and a 200-day moving average of $4.21. Over the last year, the stock registered a low of $2.08 and a high of $16.24. Nkarta holds a market capitalization of $174.31 million, with a price-to-earnings (P/E) ratio of -1.31 and a beta of 0.85, indicating lower volatility compared to the broader market.

Institutional Activity in Nkarta

Recently, several institutional investors have adjusted their positions in Nkarta. AQR Capital Management LLC entered a new position during the second quarter, investing $938,000. Federated Hermes Inc. significantly boosted its stake by 28,478.7% in the same quarter, acquiring an additional 135,274 shares, bringing their total to 135,749 shares valued at $802,000. Wasatch Advisors LP also increased its holdings by 31.7%, owning 1,834,680 shares worth $8,293,000 after procuring an extra 442,125 shares. Meanwhile, Geode Capital Management LLC raised its position by 3.0%, now holding 1,171,026 shares with a value of $5,294,000 after adding 33,927 shares. Lastly, Cubist Systematic Strategies LLC acquired a new stake valued at approximately $1,489,000. Institutional investors collectively own around 80.54% of Nkarta's stock.

Analyst Ratings for Nkarta

The sentiment of analysts concerning Nkarta has been generally optimistic. In recent reports, Mizuho decreased their price target for Nkarta from $20.00 to $16.00, maintaining an "outperform" rating. Needham & Company LLC lowered their target from $13.00 to $11.00 while still rating it as a "buy." Additionally, Rodman & Renshaw initiated coverage with a "strong-buy" rating and a $14.00 price objective. HC Wainwright also adjusted their forecast, bringing their target down from $22.00 to $18.00 but retaining a "buy" rating. There are five analysts who recommend a buy rating, alongside two who suggest a strong buy. According to MarketBeat, Nkarta currently holds a consensus rating of "Buy" with an average target price of $15.00.

About Nkarta, Inc.

Nkarta, Inc. is a clinical-stage biopharmaceutical company engaged in developing and marketing natural killer cell therapies aimed at treating cancer and autoimmune diseases. The company is advancing its lead product candidate, NKX019, which is a chimeric antigen receptor-natural killer (CAR NK) therapy targeting the CD19 antigen. NKX019 is currently in Phase 1 clinical trials for treating relapsed/refractory non-Hodgkin lymphoma and lupus nephritis.

Nkarta, Insider, Transaction